Hikma CEO's Resignation No Surprise After Stock Loss, Profit Outlook Cut -- Market Talk

Dow Jones

Dec 15, 2025

1313 GMT - Hikma Pharmaceuticals's announcement that Chief Executive Riad Mishlawi would step down today is no surprise after the company's shares fell around 25% this year, AJ Bell analysts write."[The London-based drugmaker] has been the master of its own downfall thanks to delays to a new U.K. manufacturing facility and issues in its supply chain," the analysts say. Mishlawi's departure follows a disappointing update last month that included a significantly damaging cut to medium-term profit forecasts, they write. Additional challenges include stiff competition in generic drugs, leaving investors to hope for the return of former boss Said Darwazah, they add. Shares are down 1.25% at 14.97 pounds. (william.gray@wsj.com)

(END) Dow Jones Newswires

December 15, 2025 08:13 ET (13:13 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2591492916"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591492916\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591492916?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591492916","market":"fut","top_or_hot":-1,"title":"Hikma CEO's Resignation No Surprise After Stock Loss, Profit Outlook Cut -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1313 GMT - Hikma Pharmaceuticals's announcement that Chief Executive Riad Mishlawi would step down today is no surprise after the company's shares fell around 25% this year, AJ Bell analysts write.\"[The London-based drugmaker] has been the master of its own downfall thanks to delays to a new U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. manufacturing facility and issues in its supply chain,\" the analysts say. Mishlawi's departure follows a disappointing update last month that included a significantly damaging cut to medium-term profit forecasts, they write. Additional challenges include stiff competition in generic drugs, leaving investors to hope for the return of former boss Said Darwazah, they add. Shares are down 1.25% at 14.97 pounds. (william.gray@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2025 08:13 ET (13:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hikma CEO's Resignation No Surprise After Stock Loss, Profit Outlook Cut -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHikma CEO's Resignation No Surprise After Stock Loss, Profit Outlook Cut -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-15 21:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1313 GMT - Hikma Pharmaceuticals's announcement that Chief Executive Riad Mishlawi would step down today is no surprise after the company's shares fell around 25% this year, AJ Bell analysts write.\"[The London-based drugmaker] has been the master of its own downfall thanks to delays to a new U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. manufacturing facility and issues in its supply chain,\" the analysts say. Mishlawi's departure follows a disappointing update last month that included a significantly damaging cut to medium-term profit forecasts, they write. Additional challenges include stiff competition in generic drugs, leaving investors to hope for the return of former boss Said Darwazah, they add. Shares are down 1.25% at 14.97 pounds. (william.gray@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2025 08:13 ET (13:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HKMPY","symbol_name":"Hikma Pharmaceuticals plc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2591492916","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591492916","pubTimestamp":1765804380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1313 GMT - Hikma Pharmaceuticals's announcement that Chief Executive Riad Mishlawi would step down today is no surprise after the company's shares fell around 25% this year, AJ Bell analysts write.\"[The London-based drugmaker] has been the master of its own downfall thanks to delays to a new U.K. manufacturing facility and issues in its supply chain,\" the analysts say. Mishlawi's departure follows a disappointing update last month that included a significantly damaging cut to medium-term profit forecasts, they write. Additional challenges include stiff competition in generic drugs, leaving investors to hope for the return of former boss Said Darwazah, they add. Shares are down 1.25% at 14.97 pounds. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HKMPY":"Hikma Pharmaceuticals plc.","BK4007":"制药"},"translate_title":"Hikma首席执行官在股价下跌、利润前景下调后辞职并不令人意外——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKMPY":0.9},"content_text":"1313 GMT - Hikma Pharmaceuticals's announcement that Chief Executive Riad Mishlawi would step down today is no surprise after the company's shares fell around 25% this year, AJ Bell analysts write.\"[The London-based drugmaker] has been the master of its own downfall thanks to delays to a new U.K. manufacturing facility and issues in its supply chain,\" the analysts say. Mishlawi's departure follows a disappointing update last month that included a significantly damaging cut to medium-term profit forecasts, they write. Additional challenges include stiff competition in generic drugs, leaving investors to hope for the return of former boss Said Darwazah, they add. Shares are down 1.25% at 14.97 pounds. (william.gray@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 08:13 ET (13:13 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}